Fulfilling your ablation obsession - ECIO 2025 Rotterdam overview

2025  is in full swing, and we are happy to publish our sneak preview highlighting everything that ECIO in Rotterdam has to offer regarding ablation. Spoiler alert  - we will again be showing never-before seen software features (AKA CAS-One IR version 4.3)!

Back by popular demand are the highlights for those obsessed with percutaneous tumor ablation. Below are some CASCINATION highlights as the "can't-miss" sessions that you should put on your calendar.

Before we highlight the ablation-only specifics, one topic caught our eye. CF 323 The future of IO - We have to build it. 

This is a very well-titled session, and we at CASCINATION feel it is the most important session to attend, as there is a lot at stake. Mark your calendar, Tuesday, April 15th, 10:30-12:00!

Now, back to ablation.

First of all - we invite you to come by the CASCINATION booth and see two new things:

To start, there is our AI Challenge. this is the 3rd iteration of the challenge with over 100 participants from 14 countries so far. In this iteration,  where participants can challenge themselves to "eyeball" an ablation zone to see of they are satisfied with the treatment, and then make a plan to re-treat - and see how similar it is to the CAS-One IR "reablation" feature

Secondly, a sneak-preview of CAS-One IR version 4.3. We will have a demonstration version of the brand-new, in-development software that has one MAJOR change to it! Come by to see it.

If you are new to learning about Quality Ablation with CAS-One IR, a short video can be found here

Now, for the scientific congress highlights.

In 2023 at Stockholm, there were 6 abstracts featuring CAS-One IR. 2024 in Palma had 7. This year there are 10 accepted abstracts that use or focus on CAS-One IR. 

It is very challenging to make a "short list" of sessions, but below are the ones that made our cut - make some calendar reminders or use the ECIO app to make sure you don't miss it!

ECIO 2025 Program overview

Sunday April 13^th

CF 111 - HCC management from 2020 to 2025: the revolution in...
8:30-10:00 Auditorium 1 - Moderators: P. Pereira, M. Kudo

• 111.3 ...ablation  - M. Burgmans

CF 121 - The usual suspects: IO management of osseous metastases
10:30-12:00 Auditorium 1 - Moderators: R. Cazzato, S. Tutton

• 121.3 Thermal ablation for osseous metastases: optimal lesion and modality selection - A. Kelekis
• 121.6 Bringing it all together: optimal modality combination algorithm for osseous metastases - S. Tutton

CF 122 Ethical, practical, and collaborative uses of AI in interventional oncology

10:30-12:00 Auditorium 2 - Moderators: F. Gomez Munoz, B. Meyer

• 122.3 Learning from AI successes: charting the path forward - B. Odisio

CF 123  - Understanding the "oligo" patient: progression, persistence, and resistance
10:30-12:00 Auditorium 3 - Moderators: D. Arnold, M. Meijerink

• 123.5 An update in local ablative treatments in oligometastatic disease - S. Van Der Lei

TF 142 - How to perform a safe and effective procedure
15:00-16:30 Auditorium 2 - Moderators: B. Guiu, P. Haage

• 142.1 Catheter-guided liver tumor ablation - M. Smits
• 142.2 Combined treatment of HCC: TACE and ablation - T. Jakobs
• 142.5 Electrochemotherapy for liver tumors - F. Orsi

CF143 - Meet the PI: upcoming research
15:00-16:30 Auditorium 3 - Moderators: R. Cazzato, P. Reimer

• 143.3 CRYODESMO 2 - R. Cazzato

CF152 - Mastering local treatment of metastatic colorectal cancer

• 17:00-18:30 Auditorium 2 - Moderators: J. Durand Labrunie, S. Stattner
• 152.2 Thermal ablation vs. surgical resection for small-size CRLM: the COLLISION trial aftermath - M. Meijerink
• 152.3 Percutaneous ablation vs. laparoscopic ablation CRLM - H. Pommergaard
• 152.5 Ablation of colorectal pulmonary metastases - J. Palussiere
• 152.6 Systemic and ablative treatment: when is the best timing - D. Arnold
  
  

Monday April 14^th

TB 211 - Tumor board: metastatic colorectal cancer
8:30-10:00 Auditorium 1 - Moderators: C. Sofocleous, U. Cillo

• 211.1 The ESMO treatment algorithm and treatment perspective 2025 - D. Arnold
• 211.3 Update on local ablative modalities - B. Odisio
  
  

CF 242 - Kidney cancer management
15:00-16:30 Auditorium 2 - Moderators: X. Buy, T. Wah

• 242.1 Common pitfalls to avoid in percutaneous ablation - L. Klompenhouwer
• 254.2 Stereotactic guidance, ablation planning, ablation verification in kidney cancer - R. Garcia Marcos
• 241.3 Kidney tumour ablation: RCT vs real-world evidence - D. Breen
  
  

CF 252 - Planning IO treatments and evaluating the results
17:00-18:30 Auditorium 2 - Moderators: P. Pereira, A. Adam

• 252.2 How to use functional imaging or biomarkers to improve the outcomes of tumor ablation - C. Sofocleous
• 252.3 The challenges of stereotactic thermal ablation and how technology can overcome them -  G. Laimer
  
  

Tuesday April 15^th

• 311.2 The next generation of devices - R. Iezzi
• 311.5 The role of biopsy for treatment decision - V. Paradis

CF312 - MSK roads less travelled
8:30-10:00 Auditorium 2 - Moderators: A. Ryan, J. Jennings

• 312.1 The role of fusion imaging, navigation systems, and robotics in MSK interventional oncology - D. Filipiadis
• 312.4 Sarcomas: is there a role for percutaneous ablation - M. Callstrom
• 312.5 Thermal ablation of desmoid tumors: evolution since CRYO-DESMO - A. Gangi

SP 313 - IO from neck to bone
8:30-10:00 Auditorium 3 - Moderators: L. Solbiati, E de Kerviler

• 313.3 Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study - G. Piana
• 313.6 Outcomes of thermoprotective techniques in image-guided ablation of musculoskeletal tumors - J. Jennings

TB 321 - Tumor board: renal cancer
10:30-12:00 Auditorium 1 - Moderators D. Filippiadis, X. Buy

• 321.1 When to resect ablatable tumors - P. Zondervan
• 321.2 When to ablate resectable tumors - X. Buy

• 323.2 AI in IO: navigating medical responsibilty - G. Carafiello, 
• 323.3 Is IO prepared for the future? The US perspective - R. Lewandowski
• 323.4 Is IO prepared for the future? The EU perspective - P. Pereira
• 323.5 The future generation perspective 1 - P. Varela Alvarez
• 323.6 The future generation perspective 2 - E. Efthymiou

TF 351 Tumor board: lung cancer
17:00-18:30 Auditorium 1 - Moderators: R. Suh, L Tselikas

• 351.3 Limitations of the use of thermal ablation on lung tumors - R. Grasso

SP 352 IO in liver tumors: from established to new approaches
17:00-18:30 Auditorium 2 - Moderators: M. Calandri, G. Narayanan

• 352.3 Thermal ablation versus surgical resection of small-size colorectal liver metastases: an international, randomized, controlled, phase III non-inferiority trial (COLLISION) - S. Van Der Lei
• 352.4 Long-term results of MWA in the treatment of very-early and early-stage HCC: the MARATHON study - G. Candita
• 352.5 Percutaneous cryoablation versus microwave ablation of hepatocellular carcinoma: a comparative study of safety and oncologic outcomes - D. Chlorogiannis
• 352.6 Efficacy, safety, and long-term oncological outcomes of irreversible electroporation for hepatocellular carcinoma BCLC 0, A and B: a bi-institutional retrospective study - O. Sutter

Wednesday April 16^th

TB 411 - Tumor board: HCC
8:30-10:00 - Auditorium 1 - Moderators M. Ronot, D. Pinato

• 411.2 Modern approaches to IO treatments for HCC - I. Bargellini

Good luck trying to prioritize all of these exciting sessions! We will see you there.